Prescription check.

Prescription Check: Dialysis center operator DaVita Inc. said the U.S. government asked for additional records regarding its use of Amgen Inc.'s anemia drug Epogen to determine whether the drug was being over prescribed. The Houston branch of the Office of Inspector General of the U.S. Department of Health and Human Services is seeking claims information submitted to Medicare, which spends an estimated $2 billion a year on Epogen. The red blood booster is often prescribed to fight anemia for patients whose kidneys are failing and are under regular dialysis. The U.S. Attorney's Office for the Eastern District of Pennsylvania ended its own probe last month of Epogen utilization at DaVita clinics without taking action against the company.